In a study of 497 injection drug users who had isolated presence of antibody to hepatitis B core antigen (anti-HBc) at the time of enrollment, 404 (81%) retained this condition after a mean of 49 months of follow-up, during which time no new hepatitis B surface antigen marker was detected. These findings support the hypothesis that patients with isolated presence of anti-HBc have strong resistance to reinfection and do not need vaccination.
|Journal||Clinical infectious diseases: an official publication of the Infectious Diseases Society of America|
|Publication status||Published - Oct 1 2001|
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases